Molecular subtyping of prostate cancer Review uri icon

Overview

MeSH Major

  • Oncogene Fusion
  • Prostatic Neoplasms
  • Proto-Oncogene Proteins c-ets

abstract

  • We review the recent advances in the genomic understanding of human prostate cancer, with focus on molecular subclassification. Broadly, prostate cancer can be classified based upon whether specific genomic rearrangements, such as the Transmembrane Protease, Serine 2-ETS-related gene fusion occur or whether specific alterations such as Speckle-type POZ protein and forkhead box A1 mutations occur. The molecular drivers remain to be identified in a further quarter of human prostate cancers. Depending upon the molecular subclassification and the coincident genomic alterations, specific clinical insights can be gained from this information, including associations with pathologic factors, race, and prognosis, as well as the possibility for future precision therapies.

publication date

  • March 16, 2016

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4895200

Digital Object Identifier (DOI)

  • 10.1097/MOU.0000000000000285

PubMed ID

  • 26986650

Additional Document Info